These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 15214786)

  • 1. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties.
    Fujita Y; Tsuda Y; Li T; Motoyama T; Takahashi M; Shimizu Y; Yokoi T; Sasaki Y; Ambo A; Kita A; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2004 Jul; 47(14):3591-9. PubMed ID: 15214786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2.
    Li T; Fujita Y; Tsuda Y; Miyazaki A; Ambo A; Sasaki Y; Jinsmaa Y; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2005 Jan; 48(2):586-92. PubMed ID: 15658871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mixed mu-agonist/delta-antagonist and dual mu-agonist/delta-agonist opioid ligands.
    Li T; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Lazarus LH; Okada Y
    J Med Chem; 2007 Jun; 50(12):2753-66. PubMed ID: 17497839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D-2-Nal(4)]endomorphin-2 (Antanal-2).
    Fichna J; do-Rego JC; Chung NN; Lemieux C; Schiller PW; Poels J; Broeck JV; Costentin J; Janecka A
    J Med Chem; 2007 Feb; 50(3):512-20. PubMed ID: 17266203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Dmt-Tic pharmacophore: conversion of a potent delta-opioid receptor antagonist into a potent delta agonist and ligands with mixed properties.
    Balboni G; Guerrini R; Salvadori S; Bianchi C; Rizzi D; Bryant SD; Lazarus LH
    J Med Chem; 2002 Jan; 45(3):713-20. PubMed ID: 11806723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct influence of C-terminally substituted amino acids in the Dmt-Tic pharmacophore on delta-opioid receptor selectivity and antagonism.
    Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2004 Jul; 47(16):4066-71. PubMed ID: 15267245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH.
    Balboni G; Cocco MT; Salvadori S; Romagnoli R; Sasaki Y; Okada Y; Bryant SD; Jinsmaa Y; Lazarus LH
    J Med Chem; 2005 Aug; 48(17):5608-11. PubMed ID: 16107162
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists.
    Tóth G; Ioja E; Tömböly C; Ballet S; Tourwé D; Péter A; Martinek T; Chung NN; Schiller PW; Benyhe S; Borsodi A
    J Med Chem; 2007 Jan; 50(2):328-33. PubMed ID: 17228874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity.
    Salvadori S; Balboni G; Guerrini R; Tomatis R; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1997 Sep; 40(19):3100-8. PubMed ID: 9301674
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Further studies on the Dmt-Tic pharmacophore: hydrophobic substituents at the C-terminus endow delta antagonists to manifest mu agonism or mu antagonism.
    Salvadori S; Guerrini R; Balboni G; Bianchi C; Bryant SD; Cooper PS; Lazarus LH
    J Med Chem; 1999 Dec; 42(24):5010-9. PubMed ID: 10585210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
    Agnes RS; Lee YS; Davis P; Ma SW; Badghisi H; Porreca F; Lai J; Hruby VJ
    J Med Chem; 2006 May; 49(10):2868-75. PubMed ID: 16686530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cis-4-amino-L-proline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues.
    Mollica A; Pinnen F; Stefanucci A; Feliciani F; Campestre C; Mannina L; Sobolev AP; Lucente G; Davis P; Lai J; Ma SW; Porreca F; Hruby VJ
    J Med Chem; 2012 Apr; 55(7):3027-35. PubMed ID: 22394120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Side chain methyl substitution in the delta-opioid receptor antagonist TIPP has an important effect on the activity profile.
    Tourwé D; Mannekens E; Diem TN; Verheyden P; Jaspers H; Tóth G; Péter A; Kertész I; Török G; Chung NN; Schiller PW
    J Med Chem; 1998 Dec; 41(26):5167-76. PubMed ID: 9857087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The opioid mu agonist/delta antagonist DIPP-NH(2)[Psi] produces a potent analgesic effect, no physical dependence, and less tolerance than morphine in rats.
    Schiller PW; Fundytus ME; Merovitz L; Weltrowska G; Nguyen TM; Lemieux C; Chung NN; Coderre TJ
    J Med Chem; 1999 Sep; 42(18):3520-6. PubMed ID: 10479285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
    Li T; Fujita Y; Shiotani K; Miyazaki A; Tsuda Y; Ambo A; Sasaki Y; Jinsmaa Y; Marczak E; Bryant SD; Salvadori S; Lazarus LH; Okada Y
    J Med Chem; 2005 Dec; 48(25):8035-44. PubMed ID: 16335927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis, opioid receptor binding, and bioassay of naltrindole analogues substituted in the indolic benzene moiety.
    Ananthan S; Johnson CA; Carter RL; Clayton SD; Rice KC; Xu H; Davis P; Porreca F; Rothman RB
    J Med Chem; 1998 Jul; 41(15):2872-81. PubMed ID: 9667975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokinin-1 receptor antagonists.
    Yamamoto T; Nair P; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Vanderah TW; Yamamura HI; Porreca F; Hruby VJ
    J Med Chem; 2007 Jun; 50(12):2779-86. PubMed ID: 17516639
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid receptor agonists and neurokinin 1 receptor antagonists.
    Yamamoto T; Nair P; Vagner J; Largent-Milnes T; Davis P; Ma SW; Navratilova E; Moye S; Tumati S; Lai J; Yamamura HI; Vanderah TW; Porreca F; Hruby VJ
    J Med Chem; 2008 Mar; 51(5):1369-76. PubMed ID: 18266313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pseudoproline-containing analogues of morphiceptin and endomorphin-2: evidence for a cis Tyr-Pro amide bond in the bioactive conformation.
    Keller M; Boissard C; Patiny L; Chung NN; Lemieux C; Mutter M; Schiller PW
    J Med Chem; 2001 Nov; 44(23):3896-903. PubMed ID: 11689075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and opioid activity of N,N-dimethyl-Dmt-Tic-NH-CH(R)-R' analogues: acquisition of potent delta antagonism.
    Balboni G; Salvadori S; Guerrini R; Negri L; Giannini E; Bryant SD; Jinsmaa Y; Lazarus LH
    Bioorg Med Chem; 2003 Dec; 11(24):5435-41. PubMed ID: 14642588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.